Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 8NIH 2INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 64Thoracic 13Gastrointestinal 12Head & Neck 7Gynecologic 7Breast 6Endocrine 5Sarcoma 4Other solid neoplasm 4Genitourinary 4Lymphoid 3Myeloid 2CNS 2Other hematologic neoplasm 1NET 1

Conditions

Glioblastoma 472Brain Neoplasms 306Glioma 257Neoplasms 122Astrocytoma 88Carcinoma, Non-Small-Cell Lung 76Breast Neoplasms 70Neuroblastoma 65Central Nervous System Neoplasms 61Melanoma 58Recurrence 46Lung Neoplasms 45Pancreatic Neoplasms 41Oligodendroglioma 37Ovarian Neoplasms 36Colorectal Neoplasms 36Neoplasm Metastasis 33Sarcoma 32Medulloblastoma 28Stomach Neoplasms 27Gliosarcoma 27Lymphoma 25Prostatic Neoplasms 24Head and Neck Neoplasms 24Neurofibromatosis 1 23Rhabdomyosarcoma 21Neurofibroma, Plexiform 19Esophageal Neoplasms 19Diffuse Intrinsic Pontine Glioma 19Cholangiocarcinoma 19

Interventions

LY2940680 1ADI PEG20 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Uveal Melanoma × CNS × Clear all
NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Endeavor Biomedicines, Inc.

Phase 2 Completed
20 enrolled
CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

NCT02029690 2020-09-25

TRAP

Polaris Group

Phase 1 Terminated
85 enrolled
CNSDermatologicGastrointestinal

Uveal Melanoma, Carcinoma, Glioma, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡